Noel Clarke

Noel Clarke is a urological oncologist at the Christie NHS Foundation Trust who contributed to the PROfound trial establishing olaparib as the first PARP inhibitor approved in prostate cancer for HRR-mutated mCRPC. His surgical and clinical research has advanced understanding of disease biology at the prostate-bone microenvironment interface. He has led UK cooperative group prostate cancer studies and contributed to NICE and EAU guideline development for advanced prostate cancer. His work bridges surgical oncology and systemic therapy in mCRPC management.